Merck KGaA (FRA:MRK) Stock Price Passes Above 200-Day Moving Average of $105.05

Merck KGaA (FRA:MRK)’s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $105.05 and traded as high as $122.95. Merck KGaA shares last traded at $122.70, with a volume of 227,995 shares.

Several equities research analysts have commented on the stock. DZ Bank reissued a “buy” rating on shares of Merck KGaA in a research report on Monday, February 10th. JPMorgan Chase & Co. set a €110.00 ($127.91) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Wednesday, February 5th. HSBC set a €96.00 ($111.63) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Wednesday, November 27th. Deutsche Bank set a €115.00 ($133.72) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Tuesday. Finally, Barclays set a €94.00 ($109.30) price target on shares of Merck KGaA and gave the stock a “sell” rating in a research report on Monday, January 20th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of €106.20 ($123.49).

The business’s 50-day moving average is €116.26 and its two-hundred day moving average is €105.61.

About Merck KGaA (FRA:MRK)

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: Monthly Dividend Stocks

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit